Post by cjm18 on Feb 25, 2022 9:22:05 GMT -5
Boehringer Ingelheim sells OFEV
2021 1H- Net sales of the respiratory product OFEV® increased by 28.9 percent (year on year and adjusted for currency effects) and amounted to 1.2 billion EUR. OFEV® is approved for the treatment of people living with idiopathic pulmonary fibrosis (IPF) in more than 80 countries, for systemic sclerosis-associated ILD (SSc-ILD) in more than 70 countries, and for other chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILDs) in more than 60 countries.
2020. The other drug that kept BI's pharma sales churning in 2020 was idiopathic pulmonary fibrosis med Ofev. The drug posted a sales increase of 38% to $2.34 billion, BI said.
2021 1H- Net sales of the respiratory product OFEV® increased by 28.9 percent (year on year and adjusted for currency effects) and amounted to 1.2 billion EUR. OFEV® is approved for the treatment of people living with idiopathic pulmonary fibrosis (IPF) in more than 80 countries, for systemic sclerosis-associated ILD (SSc-ILD) in more than 70 countries, and for other chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILDs) in more than 60 countries.
2020. The other drug that kept BI's pharma sales churning in 2020 was idiopathic pulmonary fibrosis med Ofev. The drug posted a sales increase of 38% to $2.34 billion, BI said.